Duodenal Ulcer

33 registered clinical trials studyying Duodenal Ulcer.

Status	Trial	Sponsor	Phase
Terminated	Systems Biology of Gastrointestinal and Related Diseases NCT05579444	Viome	—
Active Not Recruiting	To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children. NCT04702542	Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan	N/A
Completed	Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer NCT05010954	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	Phase 3
Completed	A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants Wit NCT05208268	Eisai Korea Inc.	—
Completed	A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duod NCT03553563	AstraZeneca	Phase 3
Completed	Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Wit NCT03050359	Takeda	Phase 3
Unknown	A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA NCT03057171	Yonsei University	—
Completed	Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Asp NCT02423187	Eisai Co., Ltd.	—
Completed	BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subj NCT01964131	AstraZeneca	Phase 1
Completed	Nexium Capsules LDA Specific Clinical Experience Investigation NCT01729182	AstraZeneca	—
Completed	A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Ter NCT01568398	Takeda	Phase 3
Completed	Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation NCT01562600	AstraZeneca	—
Completed	A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Ter NCT01568385	Takeda	Phase 3
Completed	Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer NCT01452724	Takeda	Phase 3
Completed	Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation NCT01435525	AstraZeneca	—
Completed	Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers NCT01199536	AstraZeneca	—
Unknown	Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets NCT01037491	Taipei Veterans General Hospital, Taiwan	N/A
Completed	Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients NCT02847455	Livzon Pharmaceutical Group Inc.	Phase 2 / Phase 3
Completed	Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-indu NCT00595517	AstraZeneca	Phase 3
Completed	Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal NCT00542789	AstraZeneca	Phase 3
Terminated	A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers NCT00762359	Takeda	Phase 3
Completed	Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflam NCT00787254	Takeda	Phase 3
Completed	Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects o NCT00441727	AstraZeneca	Phase 3
Completed	Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers NCT00284908	STEBA France	Phase 1
Completed	Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3) NCT00952978	Livzon Pharmaceutical Group Inc.	Phase 3
Completed	Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2) NCT00953381	Livzon Pharmaceutical Group Inc.	Phase 2
Completed	MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) NCT00543868	Merck Sharp & Dohme LLC	Phase 2
Unknown	Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection NCT00197418	Hamamatsu University	Phase 2 / Phase 3
Unknown	Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori NCT00149084	Hamamatsu University	Phase 3
Completed	Helicobacter Pylori Eradication With a New Sequential Treatment NCT00132171	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Phase 3
Completed	Lymphocytic Subsets and Cytokine Production With H. Pylori Infection NCT00173953	National Taiwan University Hospital	N/A
Unknown	Cytokine Gene Polymorphisms in Gastric Diseases NCT00197470	Hamamatsu University	N/A
Completed	Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection NCT00854451	National Taiwan University Hospital	Phase 4